IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 81.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 76,557 shares of the medical research company’s stock after selling 338,559 shares during the period. Royal London Asset Management Ltd.’s holdings in IQVIA were worth $15,044,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Avior Wealth Management LLC raised its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the period. Synergy Asset Management LLC acquired a new stake in IQVIA during the fourth quarter worth about $33,000. Versant Capital Management Inc raised its stake in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the period. SBI Securities Co. Ltd. acquired a new stake in IQVIA during the fourth quarter worth about $60,000. Finally, UMB Bank n.a. raised its stake in IQVIA by 72.8% during the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock worth $79,000 after acquiring an additional 169 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Truist Financial restated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Up 0.9 %

Shares of NYSE:IQV opened at $185.85 on Friday. The company has a 50 day moving average price of $194.94 and a 200 day moving average price of $208.45. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $254.54. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 24.78, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.